(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.36%) $91.45
2 days till quarter result
(amc 2024-05-06)
Expected move: +/- 6.35%
Live Chart Being Loaded With Signals
Artivion Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita Open Plus and E-vita Open Neo...
Stats | |
---|---|
本日の出来高 | 88 497.00 |
平均出来高 | 213 546 |
時価総額 | 872.99M |
EPS | $0 ( 2024-05-02 ) |
次の収益日 | ( $0.0200 ) 2024-05-06 |
Last Dividend | $0.0300 ( 2015-12-09 ) |
Next Dividend | $0 ( N/A ) |
P/E | -27.91 |
ATR14 | $0.0200 (0.10%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-20 | Stanton Marshall S. | Sell | 2 183 | Common Stock |
2024-03-15 | Green Andrew M | Sell | 1 462 | Common Stock |
2024-03-14 | Green Andrew M | Sell | 3 994 | Common Stock |
2024-03-12 | Getz Matthew A | Sell | 5 000 | Common Stock |
2024-02-23 | Horton Amy | Buy | 6 418 | Common Stock |
INSIDER POWER |
---|
41.05 |
Last 100 transactions |
Buy: 409 992 | Sell: 170 182 |
ボリューム 相関
Artivion, Inc. 相関
10 最も負の相関 | |
---|---|
CGC | -0.844 |
RENN | -0.837 |
RLX | -0.831 |
QID | -0.825 |
PSQ | -0.823 |
LGF-A | -0.821 |
LGF-B | -0.821 |
SSG | -0.819 |
IDT | -0.819 |
BZQ | -0.818 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Artivion, Inc. 相関 - 通貨/商品
Artivion, Inc. 財務諸表
Annual | 2023 |
収益: | $354.00M |
総利益: | $213.98M (60.45 %) |
EPS: | $-0.750 |
FY | 2023 |
収益: | $354.00M |
総利益: | $213.98M (60.45 %) |
EPS: | $-0.750 |
FY | 2022 |
収益: | $313.79M |
総利益: | $202.52M (64.54 %) |
EPS: | $-0.480 |
FY | 2021 |
収益: | $298.84M |
総利益: | $197.51M (66.09 %) |
EPS: | $-0.392 |
Financial Reports:
No articles found.
Artivion, Inc. Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.0250 | 2012-09-12 |
Last Dividend | $0.0300 | 2015-12-09 |
Next Dividend | $0 | N/A |
Payout Date | 2015-12-18 | |
Next Payout Date | N/A | |
# dividends | 14 | -- |
Total Paid Out | $0.395 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.28 | -- |
Div. Sustainability Score | 3.78 | |
Div.Growth Potential Score | 0.509 | |
Div. Directional Score | 2.15 | -- |
Year | Amount | Yield |
---|---|---|
2012 | $0.0500 | 1.04% |
2013 | $0.108 | 1.61% |
2014 | $0.118 | 1.06% |
2015 | $0.120 | 1.07% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
LOMA | Dividend Knight | 2023-06-30 | Quarterly | 2 | 5.23% | 8.53 |
GOF | Dividend Royal | 2023-11-14 | Monthly | 18 | 8.03% | 8.50 |
PHK | Dividend Royal | 2023-11-10 | Monthly | 22 | 6.88% | 8.50 |
ZTR | Dividend Royal | 2024-02-09 | Monthly | 37 | 8.35% | 8.50 |
PCF | Dividend King | 2023-12-18 | Monthly | 38 | 7.05% | 8.50 |
PVL | Dividend King | 2023-11-15 | Monthly | 14 | 9.37% | 8.50 |
NCV | Dividend Royal | 2024-02-09 | Monthly | 22 | 7.68% | 8.50 |
JQC | Dividend Royal | 2023-11-14 | Monthly | 22 | 6.56% | 8.50 |
SBR | Dividend Royal | 2023-11-14 | Monthly | 38 | 7.74% | 8.50 |
SCM | Dividend King | 2023-12-15 | Monthly | 13 | 7.08% | 8.50 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -0.0867 | 1.500 | -1.734 | -2.60 | [0 - 0.5] |
returnOnAssetsTTM | -0.0387 | 1.200 | -1.291 | -1.549 | [0 - 0.3] |
returnOnEquityTTM | -0.110 | 1.500 | -2.33 | -3.50 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 3.99 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 2.30 | 0.800 | 1.177 | 0.942 | [0.8 - 2.5] |
cashRatioTTM | 1.019 | 1.500 | 5.45 | 8.18 | [0.2 - 2] |
debtRatioTTM | 0.394 | -1.500 | 3.44 | -5.16 | [0 - 0.6] |
interestCoverageTTM | 0.268 | 1.000 | -1.012 | -1.012 | [3 - 30] |
operatingCashFlowPerShareTTM | 0.454 | 2.00 | 9.85 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 0.273 | 2.00 | 9.86 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 1.107 | -1.500 | 5.57 | -8.36 | [0 - 2.5] |
grossProfitMarginTTM | 0.647 | 1.000 | 2.54 | 2.54 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0192 | 1.000 | -1.617 | -1.617 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.0595 | 1.000 | -0.780 | -0.780 | [0.2 - 2] |
assetTurnoverTTM | 0.447 | 0.800 | -0.355 | -0.284 | [0.5 - 2] |
Total Score | 3.78 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -27.89 | 1.000 | -2.92 | 0 | [1 - 100] |
returnOnEquityTTM | -0.110 | 2.50 | -1.500 | -3.50 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 0.273 | 2.00 | 9.91 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 0.454 | 2.00 | 9.85 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.206 | 1.500 | -4.70 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.0525 | 1.000 | -1.188 | 0 | [0.1 - 0.5] |
Total Score | 0.509 |
Artivion, Inc.
Artivion Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita Open Plus and E-vita Open Neo. It also provides E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-nya, a thoracic stent graft system for the minimally invasive repair of lesions of the descending aorta; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, an abdominal aortic aneurysms stent graft system. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion Inc. in January 2022. The company was founded in 1984 and is headquartered in Kennesaw, Georgia.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。